pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$PODDINSULET CORP

$PODD151.51+2.35%
Acton, MA, USupdated 17h ago

An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
10
approvals ytd
0
recalls ytd
0

Pipeline(0)

no pipeline products on record

📅 Upcoming

Nov 5, 2026
earnings
$PODD151.51+2.35%
in 3mo
INSULET CORP earnings
INSULET CORP
→

🕒 Recent(90d)

earnings (2)
Aug 6, 2026
earnings
$PODD151.51+2.35%
14d ago
INSULET CORP earnings
INSULET CORP
→
Aug 5, 2026
earnings
$PODD151.51+2.35%
15d ago
INSULET CORP earnings
INSULET CORP
→
view all catalysts →

Active trials

  • —Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)recruitingn=152
  • N/AEvaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetesrecruitingn=350
  • —Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetesrecruitingn=2,200
  • N/AOmnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adultscompletedn=189
  • —French Prospective Multicentric Study in Real Worldrecruitingn=304
  • N/AAn Evaluation of the Omnipod® M System in Adults With Type 2 Diabetesactive not recruitingn=40
  • N/AEvaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Adults With Type 2 Diabetesactive not recruitingn=48
  • N/ASimplified Onboarding in Adults With Type 2 Diabetescompletedn=56
more trials →

Insider activity

source: SEC Form 4

open-market buys + sells

  • Feb 25, 26BUYMINOGUE MICHAEL R· director2,030 sh @ $246.23$500K↗
routine RSU / option mechanics (6)
  • Apr 1, 26grantPanos Michael · EVP and CCO7,255 sh
  • Apr 1, 26grantPanos Michael · EVP and CCO2,777 sh
  • Mar 31, 26grantHuffines Robert Luther · director111 sh
  • Feb 27, 26tax coverBenjamin Eric · EVP and COO644 sh
  • Feb 27, 26tax coverKapples John W. · SVP and General Counsel411 sh
  • Feb 27, 26tax coverBenjamin Eric · EVP and COO268 sh
🐶 Hiring Signal
next earnings Nov 5, 2026
No open roles indexed yet — view INSULET CORP jobs →

News

no news has mentioned this company yet
identifiers
ticker
$PODD
SEC CIK
0001145197
country
US
source
sec_tickers
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 31m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?